A first‐in‐human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics

• Váldodahkkit: Eunsol Yang (Dahkki), Hyejung Choi (Dahkki), Jin‐Sol Park (Dahkki), Young‐Woock Noh (Dahkki), Chi‐Min Choi (Dahkki), Woo‐Jong Lee (Dahkki), Jae‐Wook Ko (Dahkki), Jungryul Kim (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2021-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract KMRC011 is a novel Toll‐like receptor 5 agonist under development as a treatment for acute radiation syndrome (ARS). The aim of this first‐in‐human study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of a single intramuscular dose of KMRC011 in healthy subjects...